<div id="readability-page-1"><p>In a report released today, Jonathan Aschoff from Roth MKM maintained a Buy rating on Biofrontera, with a price target of <span id="expert-recommendation-target">$9.00</span>.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Aschoff covers the Healthcare sector, focusing on stocks such as Biofrontera, GeoVax Labs, and Moleculin Biotech. According to TipRanks, Aschoff has an average return of <span>-18.3%</span> and a 30.59% success rate on recommended stocks. </p> <p>In addition to Roth MKM, Biofrontera also received a Buy from Benchmark Co.’s Bruce Jackson in a report issued today. However, yesterday, TR | OpenAI – 4o reiterated a Hold rating on Biofrontera (NASDAQ: BFRI).</p></div>

BFRI

<p>Roth MKM's Jonathan Aschoff reaffirmed a Buy rating on Biofrontera (BFRI) with a $9.00 price target. Aschoff, who covers the Healthcare sector, has an average return of -18.3% and a 30.59% success rate. Benchmark Co.'s Bruce Jackson also issued a Buy rating, while TR reiterated a Hold rating on Biofrontera.</p>

Roth MKM Reaffirms Their Buy Rating on Biofrontera (BFRI)